PRQR - ProQR Therapeutics N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.36
+0.29 (+4.78%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.07
Open6.19
Bid6.00 x 800
Ask6.59 x 800
Day's Range5.93 - 6.39
52 Week Range5.62 - 24.00
Volume259,147
Avg. Volume164,004
Market Cap247.484M
Beta (3Y Monthly)-0.37
PE Ratio (TTM)N/A
EPS (TTM)-1.31
Earnings DateNov 5, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.91
Trade prices are not sourced from all markets
  • Benzinga

    The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) ...

  • GlobeNewswire

    ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced positive top-line results from the PQ-110-001 study, a Phase 1/2 dose range finding, first-in-human trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. “We reported today that patients receiving sepofarsen had a clinically meaningful improvement in vision, and in some cases the patient’s vision improved to a level that could be deemed life changing. This is very encouraging for the LCA10 community and the Inherited Retinal Disease community as a whole,” said Stephen R. Russell, MD, Schrage Professor of Ophthalmology and Visual Sciences and Principal Investigator at the University of Iowa.

  • GlobeNewswire

    ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

    LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that management will present and discuss top-line results from the Phase 1/2 study of sepofarsen on October 10, ahead of the American Academy of Ophthalmology's annual meeting to be held in San Francisco, CA, U.S. PQ-110-001 is a first-in-human open-label trial that enrolled 5 children (age 6 - 17 years) and 6 adults (≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. Two dose levels are being tested, 80 μg (160 μg loading dose) and 160 μg (320 μg loading dose).

  • ProQR Therapeutics Enters Oversold Territory
    Zacks

    ProQR Therapeutics Enters Oversold Territory

    ProQR Therapeutics N.V. (PRQR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • GlobeNewswire

    ProQR to Present at Two Investor Conferences in October

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.

  • Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
    Simply Wall St.

    Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
    Zacks

    Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland

    Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.

  • GlobeNewswire

    ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track designation from the Food and Drug Administration (FDA) for QR-1123. QR-1123 is a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation in the rhodopsin (RHO) gene. Fast Track designation is granted by the FDA to drugs in development for serious conditions with the potential to fulfill an unmet medical need.

  • Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study
    Zacks

    Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study

    Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.

  • Mallinckrodt Enrolls First Patient in Liver Disease Study
    Zacks

    Mallinckrodt Enrolls First Patient in Liver Disease Study

    Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.

  • GlobeNewswire

    ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for QR-1123. ProQR plans to start enrolling patients in a Phase 1/2 trial for QR-1123 in 2019. QR-1123 is a first-in-class investigational oligonucleotide designed to address the underlying cause of the vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation in the rhodopsin (RHO) gene.

  • ProQR (PRQR) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    ProQR (PRQR) Reports Q2 Loss, Misses Revenue Estimates

    ProQR (PRQR) delivered earnings and revenue surprises of 24.44% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    ProQR Announces Financial Results for the Second Quarter of 2019

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 07, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.

  • GlobeNewswire

    European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, announced today that its sepofarsen (QR-110) drug candidate, which is being developed for targeting the p.Cys998X mutation in the CEP290 gene for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the PRIority MEdicines (PRIME) program by the European Medicines Agency (EMA). As of June 2019, less than 30% (54 out of 181) of applications to the PRIME program have been granted access, and only 20% (one out of five) of ophthalmology applications have been granted access. “The EMA’s decision to grant PRIME access to sepofarsen further highlights the need for truly groundbreaking medicines to treat LCA10 patients, especially considering the rigorous selection process of the program.

  • What Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Take Home Last Year?
    Simply Wall St.

    What Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Take Home Last Year?

    Daniel de Boer became the CEO of ProQR Therapeutics N.V. (NASDAQ:PRQR) in 2012. This analysis aims first to contrast...

  • GlobeNewswire

    ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July

    LEIDEN, Netherlands and CAMBRIDGE, Mass., July 02, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • Here’s What Hedge Funds Think About ProQR Therapeutics NV (PRQR)
    Insider Monkey

    Here’s What Hedge Funds Think About ProQR Therapeutics NV (PRQR)

    Insider Monkey finished processing more than 738 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2019. In this article we are going to take a look at smart money sentiment towards ProQR Therapeutics NV (NASDAQ:PRQR). ProQR Therapeutics NV (NASDAQ:PRQR) has seen a decrease […]

  • GlobeNewswire

    ProQR to Present at the JMP Securities Life Sciences Conference

    LEIDEN, the Netherlands and CAMBRIDGE, Mass., June 03, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.

  • Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 153%?
    Simply Wall St.

    Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 153%?

    The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

  • GlobeNewswire

    ProQR to Present at the RBC Capital Markets Healthcare Conference

    LEIDEN, the Netherlands and CAMBRIDGE, Mass., May 15, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation.

  • Here is What Hedge Funds Think About ProQR Therapeutics NV (PRQR)
    Insider Monkey

    Here is What Hedge Funds Think About ProQR Therapeutics NV (PRQR)

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

  • ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates

    ProQR (PRQR) delivered earnings and revenue surprises of -13.89% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    ProQR: 1Q Earnings Snapshot

    On a per-share basis, the Leiden, Netherlands-based company said it had a loss of 41 cents. ProQR shares have fallen 30% since the beginning of the year. The stock has more than doubled in the last 12 ...

  • GlobeNewswire

    ProQR Announces Financial Results for the First Quarter of 2019

    LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • GlobeNewswire

    ProQR to Present at Three Scientific Conferences in April

    LEIDEN, Netherlands and CAMBRIDGE, Mass., April 22, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.